Vitrolife interim report January - June 2003

· Net sales for the group, after the last years divestment of business area Biosupportive Systems, amounted to SEK 48,8 million (62,5), and gross margin increased to 60% (50%), the group's net loss totalled SEK -6,6 million (-13,6).

· Net sales for core activities increased by 23 % to a total of SEK 48.8 million (39.6) and gross result increased by 40 % to SEK 29.5 million (21.2), the operating result amounted to SEK 0.1 million (-14.0).

· The group's net loss totalled SEK -4.3 million (-9.9).

· Vitrolife received FDA marketing approval of EmbryoGlue® - a breakthrough in ART (Assisted Reproductive Technology)
Gothenburg, August 13, 2003.

Vitrolife AB (Publ)

For further information, please contact:
Vitrolife

Acting CEO: Magnus Nilsson
Tel: +46 31 721 80 00
Mobile +46 708 22 80 61
[email protected]

CFO and IR agent:
Margareta Fischer
Tel: +46 31 721 80 00
Mobile: +46 708 22 80 13
[email protected]

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and four wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado), A-Life Ltd. (Edinburgh, Scotland), and A-Life Inc. (Newport Beach, California). The group's operations focused on three geographic areas.

· Europe/Middle East
· North America
· Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.